Deal-Making Perspectives: GSK/Pfizer HIV Venture Offers Transformational Strategy
Executive Summary
Real innovation in deal-making, like pharma R&D, is a rare commodity. As with R&D, deal-making innovation often gets blocked by entrenched interests or misunderstanding or simple inertia. There are lots of reasons not to repeat the single most innovative and successful transaction of all time - Genentech/Roche - but none of them outweigh the spectacular opportunity that deal created